Surgical stress promotes the development of cancer metastases by a coagulation-dependent mechanism involving natural killer cells in a murine model

Annals of Surgery

Volumn 258, Issue 1, 2013, Pages 158-168

  Seth, Rashmi ^a,b   Tai, Lee Hwa ^b   Falls, Theresa ^b   De Souza, Christiano T ^b   Bell, John C ^b   Carrier, Marc ^c   Atkins, Harold ^b,c   Boushey, Robin ^a   Auer, Rebecca A ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Cancer metastases; Coagulation; Murine model; Natural killer cells; Surgical stress

Indexed keywords

FIBRINOGEN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; FEMALE; LUNG METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; SURGICAL STRESS; THROMBOCYTE;

ANALYSIS OF VARIANCE; ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DISEASE MODELS, ANIMAL; FEMALE; KILLER CELLS, NATURAL; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; NEOPLASTIC CELLS, CIRCULATING; P-SELECTIN; STRESS, PHYSIOLOGICAL; SURGICAL PROCEDURES, OPERATIVE;

EID: 84879114434     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31826fcbdb     Document Type: Article

References (53)

1. Tyzzer EE. Factors in the production and growth of tumor metastases. J Med Res. 1913;28:309-321.
2. Shiromizu A, Suematsu T, Yamaguchi K, et al. Effect of laparotomy and laparoscopy on the establishment of lung metastasis in a murine model. Surgery. 2000;128:799-805.
3. Ben-Eliyahu S, Page GG, Yirmiya R, et al. Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int J Cancer. 1999;80:880-888.
4. Tsuchiya Y, Sawada S, Yoshioka I, et al. Increased surgical stress promotes tumor metastasis. Surgery. 2003;133:547-555.
5. Colacchio TA, Yeager MP, Hildebrandt LW. Perioperative immunomodulation in cancer surgery. Am J Surg. 1994;167:174-179.
6. Da Costa ML, Redmond P, Bouchier-Hayes DJ. The effect of laparotomy and laparoscopy on the establishment of spontaneous tumor metastases. Surgery. 1998;124:516-525.
7. Glasner A, Avraham R, Rosenne E, et al. Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J Immunol. 2010;184:2449-2457.
8. Benish M, Bartal I, Goldfarb Y, et al. Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol. 2008;15:2042-2052.
9. Goldfarb Y, Sorski L, Benish M, et al. Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses. Ann Surg. 2011;253:798-810.
10. Xu WF, Andersen H, Whitmore TE, et al. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci U S A. 1998;95:6642-6646.
11. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2007;27:1687-1693.
12. McCrath DJ, Cerboni E, Frumento RJ, et al. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg. 2005;100:1576-1583.
13. Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst. 1999;91:22-36.
14. Gasic GJ, Gasic TB, Galanti N, et al. Platelet-tumor-cell interactions in mice. The role of platelets in the spread of malignant disease. Int J Cancer. 1973;11:704-718.
15. Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A. 1968;61:46-52.
16. Varki NM, Varki A. Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin Thromb Hemost. 2002;28:53-66.
17. Kirstein JM, Graham KC, Mackenzie LT, et al. Effect of anti-fibrinolytic therapy on experimental melanomametastasis. Clin Exp Metastasis. 2009;26:121-131.
18. Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96:3302-3309.
19. Palumbo JS, Potter JM, Kaplan LS, et al. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res. 2002;62:6966-6972.
20. Sierko E, Wojtukiewicz MZ. Inhibition of platelet function: does it offer a chance of better cancer progression control? Semin Thromb Hemost. 2007;33:712-721.
21. Tang DG, Honn KV. Adhesion molecules and tumor metastasis: an update. Invasion Metastasis. 1994;14:109-122.
22. Nierodzik ML, Klepfish A, Karpatkin S. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost. 1995;74:282-290.
23. Chopra H, Timar J, Rong X, et al. Is there a role for the tumor cell integrin alpha IIb beta 3 and cytoskeleton in tumor cell-platelet interaction? Clin Exp Metastasis. 1992;10:125-137.
24. Palumbo JS, Talmage KE, Massari JV, et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood. 2007;110:133-141.
25. Nieswandt B, Hafner M, Echtenacher B, et al. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999;59:1295-1300.
26. Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin (ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105:178-185.
27. Gorelik E. Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice. Cancer Res. 1987;47:809-815.
28. Gorelik E, Bere WW, Herberman RB. Role of NK cells in the antimetastatic effect of anticoagulant drugs. Int J Cancer. 1984;33:87-94.
29. Lazo-Langner A, Goss GD, Spaans JN, et al. The effect of low-molecularweight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost. 2007;5:729-737.
30. Kingston RD, Fielding JW, Palmer MK. Peri-operative heparin: a possible adjuvant to surgery in colo-rectal cancer? Int J Colorectal Dis. 1993;8:111-115.
31. Von Tempelhoff GF, Harenberg J, Niemann F, et al. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized doubleblind trial. Int J Oncol. 2000;16:815-824.
32. Andre P, Hartwell D, Hrachovinova I, et al. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci U S A. 2000;97:13835-13840.
33. Stevenson JL, Choi SH, Varki A. Differentialmetastasis inhibition by clinically relevant levels of heparins-correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res. 2005;11:7003-7011.
34. Lund EL, Olsen MW, Lipson KE, et al. Improved effect of an antiangiogenic tyrosine kinase inhibitor (SU5416) by combinations with fractionated radiotherapy or low molecular weight heparin. Neoplasia. 2003;5:155-160.
35. Esumi N, Fidler IJ. Inhibition of mouse melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res. 1991;51:4549-4556.
36. Parker AL, Waddington SN, Nicol CG. Multiple vitamin K-dependent coagulation zymogens promote Ad-mediated gene delivery to hepatocytes. Blood. 2006;108:2554-2561.
37. Mousa SA, Petersen LJ. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb Haemost. 2009;102:258-267.
38. Gorelik E, Wiltrout RH, Okumura K, et al. Role of NK cells in the control of metastatic spread and growth of tumor cells in mice. Int J Cancer. 1982;30:107-112.
39. Hanna N. The role of natural killer cells in the control of tumor growth and metastasis. Biochim Biophys Acta. 1985;780:213-226.
40. Akl EA, Barba M, Rohilla S, et al. Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patientswith cancer: a cochrane systematic review. J Exp Clin Cancer Res. 2008;27:21.
41. Wenzel J, Zeisig R, Fichtner I. Inhibition of metastasis in a murine 4T1 breast cancer model by liposomes preventing tumor cell-platelet interactions. Clin Exp Metastasis. 2010;27:25-34.
42. Collen A, Smorenburg SM, Peters E, et al. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res. 2000;60:6196-6200.
43. Dvorak HF, Senger DR, Dvorak AM. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev. 1983;2:41-73.
44. Ogawa K, Hirai M, Katsube T, et al. Suppression of cellular immunity by surgical stress. Surgery. 2000;127:329-336.
45. Gunji Y, Lewis J, Gorelik E. Fibrin formation inhibits the in vitro cytotoxic activity of human natural and lymphokine-activated killer cells. Blood Coagul Fibrinolysis. 1990;1:663-672.
46. Atagi S, Sone S, Fukuta K, et al. Inhibition by fibrin coagulation of lung cancer cell destruction by human interleukin-2-activated killer cells. Jpn J Cancer Res. 1992;83:1088-1094.
47. Vetvicka V, Thornton BP, Wieman TJ, et al. Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18). J Immunol. 1997;159:599-605.
48. Tykocinski ML, Xiong N, Morrow DM. Platelet immunoregulatory factors. Stem Cells. 1996;14:240-245.
49. Kopp HG, Placke T, Salih HR. Platelet-derived transforming growth factorbeta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 2009;69:7775-7783.
50. Lee JC, Lee KM, Kim DW, et al. Elevated TGF-beta1 secretion and downmodulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol. 2004;172:7335-7340.
51. Borsig L, Wong R, Hynes RO, et al. Synergistic effects of L-and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci U S A. 2002;99:2193-2198.
52. Auer RC, Scheer AS, McSparron JI, et al. Postoperative venous thromboembolism predicts survival in cancer patients. Ann Surg. 2012;255:963-970.
53. ClinicalTrials.gov. NCT01455831: Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colon Cancer (PERIOP-01). National Institutes of Health.